Last month, the FDA approved Beovu (brolucizumab-dbll) from Novartis Pharmaceuticals Corp. for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see brief, p. 8). The intravitreal injection will compete in a fairly crowded anti-vascular endothelial growth factor (anti-VEGF) market that is led by Eylea (aflibercept) from Regeneron Pharmaceuticals, Inc.
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits
- Headlines in the News
- Abstract, Medicare and Medicaid